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0959-8049/ª 2020 Published by ElsevieAbstract Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive cancer that
remains very hard to treat. The life expectancy of a patient diagnosed with this disease has
not changed over the past three decades. Recently, three large clinical studies showed a sur-
vival benefit by adding an antieprogrammed death (ligand) 1 (PD-(L)1 antibody to the
current chemotherapy regimen. Although significant and important, the benefit seems less
than what has been achieved in patients with nonesmall-cell lung cancer treated with che-
moimmunotherapy. A number of hypotheses have been explored to explain this discrepancy.
Here, we hypothesise that the current chemotherapy backbone in ES-SCLC does not contain
the optimal drugs to trigger immunogenic cell death and therefore does not induce a synergy
between chemotherapy and immune checkpoint inhibitor therapy. Thereby, we advocate that
doxorubicin treatment instead of etoposide should be reconsidered as standard-of-care (SoC)
first-line treatment of SCLC.
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cancer. At diagnosis, approximately two-third of the
patients are diagnosed with extensive-stage (ES) disease.
ES-SCLC treatment options remain limited, resulting in
a poor prognosis that did not improve in the past three
decades. For many years, the standard-of-care (SoC)
treatment regimen most used for patients with ES-SCLC
consists of 4e6 cycles of platinum-based chemotherapy
(cisplatin/carboplatin) and etoposide. ES-SCLC re-
sponds well to chemotherapy, but recurrence of disease
develops rapidly [1].
The treatment landscape of thoracic malignancies in
general changed dramatically in the past decades, due to
the discovery of immune checkpoint inhibitor (ICI)
therapy, i.e. programmed death 1 (PD-1), programmed
death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-
eassociated antigen 4 (CTLA-4) monoclonal antibodies
[2]. Nonetheless, it should be noted that within the
thoracic malignancies mainly patients with nonesmall-
cell lung cancer (NSCLC) benefit from this discovery [3].
However, two important factors hinted towards a
beneficial role for ICI in ES-SCLC. First, the response
to chemotherapy, which is seen in the majority of pa-
tients with ES-SCLC, induces a reduction in tumour
burden and thus potentially in the immunosuppressive
environment created by the tumour, which is beneficial
for ICI response [4]. Second, the high tumour muta-
tional burden (TMB) described in ES-SCLC, potentially
resulting in a large number of neoantigens, has been
shown to be a promising predictive biomarker of ICI
efficacy in several types of cancer. Although the pre-
dictive value of TMB appeared to be limited in pro-
spective clinical studies, high TMB in ES-SCLC did
raise hope for similar ICI clinical responses in SCLC
and NSCLC tumours [5].
Various clinical trials investigated checkpoint
blockade in ES-SCLC. Results of single-agent check-
point inhibitor trials in the second-line or later setting,
have been disappointing as benefit was limited, in
contrast to the results seen in NSCLC. AntiePD-1
antibody treatment, with or without the addition of
anti-CTLA, has been explored in the single arm trials of
Checkmate 032 [6] KEYNOTE-028 [7] and KEYNOTE-
158 [8]. The pooled analysis of KEYNOTE-028 and
KEYNOTE-158 reported a response rate of 19,3%,
(95% confidence interval [CI]: 11.4e29.4), a median
progression-free survival (PFS) of 2.0 months (95% CI:
1.9e3.4) and a median overall survival (OS) of 7.7
months (95% CI: 5.2e10.1) [9]. Checkmate 331 [10] and
IFCT-1603 [11] compared SoC chemotherapy to nivo-
lumab and atezolizumab, respectively, but both failed to
improve OS in patients with SCLC requiring second-line
treatment. Furthermore, single-agent antiePD-1 treat-
ment in third-line setting has been investigated in single-
arm trials and US Food and Drug Administration
approval was granted based on objective response rates
of only 10e20%. In NSCLC in contrast, higher numberof responders and more durable responses to single-
agent ICI are seen [12e14].
The high sensitivity to chemotherapy that character-
ises most SCLCs, results in massive tumour antigen
release from dying tumour cells, which theoretically
renders these tumours as sensitive to ICI as NSCLC tu-
mours. A number of phase III clinical trials investigated
this strategy. The first phase III clinical trial that inves-
tigated ICI-therapy in combination with first-line
therapy, studied the role of an antieCTLA-4 antibody
in combination with platinum and etoposide. No differ-
ence was established in PFS nor OS [15]. Furthermore,
the IMpower133 phase III randomised trial evaluated the
efficacy and safety of atezolizumab (antiePD-L1) with
carboplatin and eetoposide. The study showed a signif-
icant improvement in PFS (hazard ratio for disease
progression or death: 0.77; 95% CI: 0.62e0.96; PZ 0.02)
and OS (hazard ratio for death: 0.70; 95% CI: 0.54 to
0.91; p Z 0.007), but response rates did not differ
between the two arms [16]. The phase III, randomised
CASPIAN trial assessed first-line durvalumab
(antiePD-L1) and etoposide with either cisplatin or
carboplatin versus platinum-etoposide alone. This
resulted in significantly longer OS (HR for disease pro-
gression or death: 0.73; 95% CI: 0.59e0.91; PZ 0.0047).
Significance of PFS could not be tested due to the study
design, but median PFS was 5.1 in the combination
treatment arm versus 5.4 months in the platinum-
etoposide alone arm, resulting in a HR of 0.78 (95% CI:
0.65e0.94) [17]. The KEYNOTE-604 phase III rando-
mised trial evaluated the addition of pembrolizumab
(antiePD-1) to etoposide-platinum (either cisplatin or
carboplatin) versus placebo/etoposide-platinum. A prior
interim analysis demonstrated a significant improvement
in PFS (HR for disease progression: 0.75; 95% CI:
0.61e0.91). Although OS did improve as well, the OS
results did not meet the criteria for statistical significance
per the pre-specified statistical plan (HR for death: 0.80;
95% CI: 0.64e0.98) [18]. In conclusion, the clinical trials
summarised here demonstrated significant differences in
favour of the chemotherapy ICI combination treatment
arm, but only aminority of patients with ES-SCLC seems
to benefit from ICI in combination with chemotherapy.
No biomarker is yet to be found to identify this minority,
partly due to the confounding nature of the chemo-
sensitive SCLC tumours. In NSCLC, the benefit from
chemotherapy ICI combination treatment compared
with chemotherapy only, is much more pronounced.
KEYNOTE-189 investigated SoC chemotherapy plus
pembrolizumab versus SoC chemotherapy plus placebo
in NSCLC and found a hazard ratio for progression or
death of 0.52 (95% CI: 0.43 to 0.64; P < 0.001) and
12-month OS rate of 61.7% vs. 52.2% (hazard ratio for
death: 0.59; 95% CI: 0.38 to 0.92) in the pembrolizumab
vs. placebo groups [19]. Currently, there is also in
NSCLC no biomarker available to predict improved
outcome on combination treatment.
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SCLC clinical responses to chemotherapy ICI combi-
nation treatment. SCLC tends to be intrinsically more
resistant to ICI than NSCLC, and different mechanisms
of resistance are likely to be in place. In NSCLC, ben-
efits in terms of response rates, PFS and OS are poten-
tially due to synergistic effects of the two treatment
modalities. It stands out that in SCLC combination
trials, a clear separation of the PFS and OS curves can
only be seen after 4e7 months. Late separation of the
curves, in addition to the lack of improvement in
response rates, do support the absence of a synergistic
effect between the two treatment modalities. In this brief
report, we explore the optimal chemotherapy backbone
for ICI combination treatment in SCLC, aiming for true
synergy.
Immunogenic cell death (ICD) is a key mechanism in
the process of immune modulation by cytotoxic
chemotherapies. ICD results in regulated activation of
an immune response, in the absence of ‘pathogen-asso-
ciated molecule patterns’. In contrast, ‘damage-associ-
ated molecular patterns’ (DAMPs), molecules that areFig. 1. Differences in the immunological response to dying tumour cell
motherapies and etoposide. The left panel of this figure depicts how IC
immune response by CD8 T cells. First (1), chemotherapy can induce e
ER stress, the ER protein calreticulin (CALR) translocates to the tumo
pattern (DAMP), and this damage signal stimulates DCs to take up t
and CD8 T cells by displaying the appropriate peptide-MHC ligand,
naive CD8 T cells generates cytotoxic effector CD8 T cells that are cap
this figure depicts the lack of T cell activation during etoposide treatme
on the tumour cell surface, thereby diminishing activation and matura
and to activate CD4 and CD8 T cells. As a result, T cell activation and
is not initiated. CALR Z calreticulin, ER stress Z endoplasmatic reticexpressed or released upon cellular stress responses or
cell death, can exert powerful immunogenic signals by
binding to pattern recognition receptors on immune
cells. These signals activate a cascade, resulting in the
activation of cytotoxic CD8 T cells that can eliminate
tumour cells. So far, 4 key DAMPs have been recog-
nised to play an important role in chemotherapy-
induced ICD [20]. First, the release of the nuclear
protein non-histone chromatin-binding protein
high-mobility group box 1 (HMGB1) into the extracel-
lular space can activate Toll-like receptor 4 that is
expressed on dendritic cells (DCs). Second, type I
interferon signalling by dying cancer cells can upregulate
chemotactic factors on surrounding cells that help
attract T cells to the tumour site. Third, if apoptotic cell
death is preceded by autophagy, ATP can be released
and attract myeloid cells. And finally, the ER protein
calreticulin (CALR) translocates to the cell membrane
in response to the induction of endoplasmatic reticulum
(ER) stress, and provides an important ‘eat-me’ signal to
antigen-presenting cells, by interacting with CD91 on
the engulfing cell [21]. CALR appears to play a vital roles that is initiated by immunogenic cell death (ICD)einducing che-
D inducing chemotherapies can promote a cytotoxic anti-tumour
ndoplasmatic reticulum (ER) stress in tumour cells. In response to
ur cell surface. CALR functions as a damage-associated molecular
umour antigens (3). In response, DCs will mature and prime CD4
which promotes T cell activation and proliferation (4). Priming of
able of direct tumour cell killing (5). In contrast, the right panel of
nt. Because etoposide is not a potent ICD inducer, CALR is absent
tion of DCs. These DCs are less likely to take up tumour antigens
proliferation does not occur and a cytotoxic anti-tumour response
ulum stress, DC Z dendritic cell, ICD Z immunogenic cell death.
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Obeid et al. [22] performed a number of in vitro and
in vivo experiments and concluded that CALR exposure
was necessary for successful ICD. First, they found that
anthracyclins are highly efficient ICD inducers and that
the immunogenicity of anthracyclins could be abrogated
by the blockade or knockdown of CALR, which in turn
suppressed phagocytosis of dying tumour cells by DCs.
On the other hand, CALR translocation was lacking in
etoposide-treated mice and administration of recombi-
nant CALR could restore ICD and enhance anti-
tumour effects in this treatment regimen. Bezu et al. [20]
supported these findings in their review and concluded
that, even though etoposide does regulate ATP secretion
and HMGB1 release, CALR translocation was inevi-
table for successful ICD induction. In conclusion, the
lack of CALR translocation may be a key feature that is
missing in patients treated with platinum-etoposide and
ICI (Fig. 1).
Until 2000, anthracyclin-based chemotherapy in the
form of doxorubicin was used in Europe as the SoC
regimen for first-line treatment in SCLC [23]. Doxoru-
bicin and etoposide share the same molecular targets
and induce DNA double-stranded breaks in an almost
identical manner. Clinical benefit of platinum-etoposide
and doxorubicin regimens was shown to be similar in
several trials. A meta-analysis of cisplatin containing
regimens versus regimens without platinum however,
put doxorubicin to the second place of SCLC treatment
[24]. Now, in the light of ICD induction, doxorubicin
treatment for SCLC should be brought back under
consideration.
Because the current regimen consists of etoposide
combined with cisplatin or carboplatin, it is inevitable in
this context to also consider the immunogenic capacities
of platinum agents. It is important to notice that
chemically related chemotherapeutic agents can have
entirely different capacities to trigger ICD. Preclinical
studies showed that cisplatin is intrinsically incapable of
inducing ICD, due to the lack of ER stressedependent
CALR translocation [25]. Carboplatin induces cell death
in a similar manner to cisplatin [26]. Oxaliplatin on the
contrary, is known to be a powerful ICD inducer.
However, oxaliplatin has not been proved to be effective
in SCLC and thus the platinum chemotherapeutics
appear not to be the right agents to combine with ICI in
the context of SCLC.
It should be mentioned, that etoposide combination
treatment was also one of the potential agents used in
the PACIFIC trial. This trial investigated the benefit of
adding durvalumab as maintenance treatment in stage
III NSCLC [27]. Approximately one quarter of patients
received etoposide, and up to this date, no data are
present on differences in efficacy of the chemotherapy
arms. But one should realise that these patients were
irradiated concurrently and radiotherapy is known to bea potent ICD inducer. This may have reduced the need
for DAMP release induced by chemotherapy.
In conclusion, although exciting new treatment
options are developed by combining chemotherapy and
ICI, the combination should be designed with care. By
adding chemotherapy to ICI, we should aim to reinforce
tumour immunogenicity and alleviate immunosuppres-
sion. Therefore, we argue that a systematic investigation
of ICD inducing capacities of currently available che-
motherapies for SCLC is urgently needed. This knowl-
edge should be the basis for further clinical investigations.Conflict of interest statement
J.G.J.V.A reports being a member of the advisory
board for and/or received speakers fee from Eli Lilly,
Roche, Boehringer Ingelheim, BMS, AstraZeneca and
MSD; is a stock owner of Amphera B.V. Immuno-
therapy; has a patent pending on tumour lysate antigen.
D.W.D. has received speakers fee from Roche, Novartis,
BMS, MSD, AstraZeneca and Pfizer. All the remaining
authors have declared no conflicts of interest.
References
[1] FrühM, de Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small-
cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up y. ESMO Updated Clin Pract
Guideline 2013;24:vi99e105. https://doi.org/10.1093/annonc/mdt178.
[2] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint
blockade. Science 2018. https://doi.org/10.1126/science.aar4060.
[3] Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G,
Imbimbo M, et al. Choosing wisely first line immunotherapy in
non-small cell lung cancer (NSCLC): what to add and what to
leave out. Canc Treat Rev 2019;75:39e51. https:
//doi.org/10.1016/j.ctrv.2019.03.004.
[4] Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B,
Manne S, et al. T-cell invigoration to tumour burden ratio asso-
ciated with anti-PD-1 response. Nature 2017. https:
//doi.org/10.1038/nature22079.
[5] Samstein RM, Lee C-H, Shoushtari AN, Hellman MD, Shen R,
Janjigian YY, et al. Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Gen January
2019;1. https://doi.org/10.1038/s41588-018-0312-8.
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